Jefferies Financial Group Has Lowered Expectations for Elevance Health (NYSE:ELV) Stock Price

Elevance Health (NYSE:ELV) had its price target lowered by research analysts at Jefferies Financial Group from $401.00 to $395.00 in a research note issued to investors on Friday,MarketScreener reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 14.29% from the company’s previous close.

A number of other analysts have also issued reports on the stock. Sanford C. Bernstein dropped their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a research note on Friday. Bank of America lifted their price objective on shares of Elevance Health from $330.00 to $370.00 and gave the stock a “neutral” rating in a report on Friday, October 10th. Zacks Research raised Elevance Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 6th. Leerink Partners raised their target price on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a research report on Thursday. Finally, Wolfe Research set a $425.00 target price on Elevance Health and gave the stock an “outperform” rating in a report on Thursday, January 8th. Thirteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $396.90.

Elevance Health Stock Down 0.4%

Shares of ELV opened at $345.62 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54. Elevance Health has a 1 year low of $273.71 and a 1 year high of $458.75. The stock has a market capitalization of $76.81 billion, a PE ratio of 13.76, a P/E/G ratio of 1.88 and a beta of 0.51. The company’s 50-day simple moving average is $351.69 and its 200-day simple moving average is $329.03.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts forecast that Elevance Health will post 33.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Elevance Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Evergreen Wealth Management LLC lifted its position in shares of Elevance Health by 33.5% in the 3rd quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after purchasing an additional 4,336 shares during the period. Canoe Financial LP grew its stake in shares of Elevance Health by 18.1% in the third quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock worth $125,823,000 after acquiring an additional 59,743 shares during the last quarter. Synergy Asset Management LLC increased its stake in Elevance Health by 100.0% during the 3rd quarter. Synergy Asset Management LLC now owns 104,334 shares of the company’s stock valued at $33,712,000 after purchasing an additional 52,167 shares in the last quarter. Delta Investment Management LLC purchased a new position in Elevance Health in the 3rd quarter worth approximately $7,629,000. Finally, OLD National Bancorp IN boosted its position in shares of Elevance Health by 44.8% during the second quarter. OLD National Bancorp IN now owns 6,267 shares of the company’s stock valued at $2,438,000 after buying an additional 1,939 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.